Nordic News, Business and Life in Asia
Novo Nordisk will lose patent protection for its blockbuster drug Ozempic in several major markets from Saturday. The patent expiry opens the door for other manufacturers to produce cheaper generic …
Novo Nordisk will lose patent protection on Saturday Read More
A Chinese biotechnology company, Shanghai Shiling Pharmaceutical, plans to complete clinical trials by 2028 for a weight-loss nasal spray that uses semaglutide, the same active ingredient as Danish drugmaker Novo Nordisk’s …
Chinese biotech develops semaglutide spray as Novo Nordisk patent expires in China Read More
Novo Nordisk said China’s Supreme People’s Court has upheld the validity of its semaglutide compound patent, according to a company statement issued on Saturday. China’s Supreme People’s Court thereby confirmed …
Novo Nordisk says China court upholds its semaglutide patent Read More
The Chinese version of the Novo Nordisk Semaglutide injection Wegovy has gotten the green light to begin clinical trials for weight loss treatment. The drug is developed by CSPC Pharmaceutical …
Chinese version of Novo Nordisk drug gets green light Read More
Novo Nordisk has established itself in the medicine market with patents that earn billions. Mainly due to the obesity drug Wegovy and the diabetes medicine Ozempic. Both consists of an …
Approaching patent expiration in China may threaten Novo’s billion-dollar business Read More
Danish Novo Nordisk reported Thursday, May 4, a 39% increase in first-quarter profits, due to the company’s sales of obesity treatments. From January to March, net profit reached 19.8 billion …
Novo Nordisk experience big profit rise due to obesity treatments Read More